share_log

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

Theralase(R) Demonstrates 8 Year Shelf Life of Lead Drug Ruvidar(TM)

Theralase (R) 演示鉛藥物 Ruvidar (TM) 的保質期爲 8 年
Accesswire ·  2023/09/29 19:00

TORONTO, ON / ACCESSWIRE / September 29, 2023 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF) is a clinical stage pharmaceutical company that is dedicated to the research and development of light and radiation activated Photo Dynamic Compounds ("PDCs"), their associated drug formulations and the light systems that activate them. These PDCs are intended to safely and effectively destroy various cancers, bacteria and viruses, when light or radiation activated.

安大略省多倫多/ACCESSWIRE/2023 年 9 月 29 日/Thelase Technologies IncTheralase“或者”公司“) (TSXV: TLT) (OTCQB: TLTFF) 是一家臨床階段的製藥公司,致力於研究和開發光和輻射活化合物 Photo Dynamic Compounds (”PDC“),它們的相關藥物配方和激活它們的光系統。當光線或輻射激活時,這些PDC旨在安全有效地消滅各種癌症、細菌和病毒。

Supported by current Good Manufacturing Practice ("cGMP") analysis conducted by an independent manufacturing and testing laboratory, Theralase announced that it has successfully demonstrated an 8 year, real-time, shelf life of its lead PDC, RuvidarTM.

由當前《良好生產規範》支持 (”cGMP“) 由獨立的製造和測試實驗室進行的分析,Theralase宣佈,它已成功證明其主要PDC Ruvidar的保質期爲8年、實時TM

Dr. Arkady Mandel, MD, PhD, DSc, Chief Scientific Officer of Theralase stated, "Theralase's ability to demonstrate such an extended shelf life of its lead PDC, RuvidarTM is extremely encouraging, as it supports our ongoing clinical development plans. This independent analysis confirms the ability of RuvidarTM to be an extremely stable small molecule that has the ability to maintain its potency and purity over 8 years without significant degradation. This will allow our clinical partners to procure and store our PDC technology over many years without loss of clinical performance, minimizing the requirement to dispose of / replace unused drug over time."

Theralase首席科學官、醫學博士、博士、理學博士Arkady Mandel博士說:“Theralase有能力證明其主導產品Ruvidar的保質期如此長TM 非常令人鼓舞,因爲它支持了我們正在進行的臨床開發計劃。這項獨立分析證實了Ruvidar的能力TM 是一種極其穩定的小分子,能夠在8年內保持其效力和純度,而不會出現明顯的降解。這將使我們的臨床合作伙伴能夠在多年內採購和儲存我們的PDC技術,而不會損失臨床表現,從而最大限度地減少隨着時間的推移處置/更換未使用藥物的需求。”

Mr. Roger DuMoulin-White, BSc, P.Eng, Pro.Dir, President and Chief Executive Officer of Theralase stated, "Since 2015, Theralase has utilized the services of an external, independent testing laboratory to conduct accelerated aging and real time stability studies in the storage of RuvidarTM, with the goal of validating product purity and hence efficacy over time. The recent stability report validates the storage of RuvidarTM over 8 years, providing Theralase additional support that it's lead drug can be successfully manufactured and sterilized, then subsequently stored at clinical study sites around the globe for many years. This extended shelf life allows our future commercial partners to be confident in the ability to procure and store our lead drug without risk of degradation of clinical performance over time. This will significantly reduce the cost of replacement of the drug due to spoilage / lack of efficacy. As a result of the latest report, Theralase will continue to leverage our expertise in the research and development of new PDC formulations, such as Rutherrin, to allow our anti-cancer technology to be available for additional cancer indications."

Theralase總裁兼首席執行官Roger Dumoulin-White先生表示:“自2015年以來,Theralase一直利用外部獨立測試實驗室的服務對Ruvidar的存儲進行加速老化和實時穩定性研究TM,目標是隨着時間的推移驗證產品的純度,從而驗證其功效。最近的穩定性報告證實了Ruvidar的存儲TM 超過8年,爲Theralase提供了額外的支持,使其主要藥物可以成功製造和消毒,然後在全球各地的臨床研究中心儲存多年。保質期的延長使我們未來的商業合作伙伴能夠對採購和儲存我們的先導藥物充滿信心,而不會隨着時間的推移臨床表現下降的風險。這將大大降低因變質/缺乏療效而更換藥物的成本。根據最新報告,Theralase將繼續利用我們在研發新的PDC配方(例如Rutherrin)方面的專業知識,使我們的抗癌技術能夠用於其他癌症適應症。”

About Theralase Technologies Inc.:
Theralase is a clinical stage pharmaceutical company dedicated to the research and development of light and radiation activated compounds, their associated drug formulations and the light systems that activate them, with a primary objective of efficacy and a secondary objective of safety in the destruction of various cancers, bacteria and viruses.

關於 Theralase 科技公司:
Theralase是一家臨床階段的製藥公司,致力於研究和開發光和輻射活化合物、其相關藥物配方和激活它們的光系統,其主要目標是療效,次要目標是銷燬各種癌症、細菌和病毒的安全性。

Additional information is available at and

更多信息可在和

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

多倫多證券交易所風險投資交易所及其監管服務提供商(該術語在多倫多證券交易所風險交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Forward Looking Statements

前瞻性陳述

This news release contains Forward-Looking Statements ("FLS") within the meaning of applicable Canadian securities laws. Such statements include, but are not limited to, statements regarding the Company's proposed development plans with respect to Photo Dynamic Compounds ("PDCs") and their drug formulations. FLS may be identified by the use of the words "may, "should", "will", "anticipates", "believes", "plans", "expects", "estimate", "potential for" and similar expressions; including, statements related to the current expectations of the Company's management for future research, development and commercialization of the Company's PDCs and their drug formulations; including: preclinical research, clinical studies and development and regulatory approvals.

本新聞稿包含前瞻性陳述(”FLS“) 在適用的加拿大證券法的含義範圍內。此類聲明包括但不限於有關公司在Photo Dynamic Compounds方面的擬議開發計劃的聲明(”PDC“)及其藥物配方。FLS 可以通過使用 “” 一詞來識別可能,”應該“,”“,”預期“,”相信“,”計劃“,”期待“,”估計“,”潛力“以及類似的表述;包括與公司管理層當前對公司PDC及其藥物配方未來研究、開發和商業化的預期有關的聲明;包括:臨床前研究、臨床研究和開發以及監管部門的批准。

These statements involve significant risks, uncertainties and assumptions; including, whether the Company is able to: adequately fund and secure the requisite regulatory approvals to successfully complete preclinical and clinical studies in a timely fashion to implement its development plan; successfully commercialize its drug formulations; access sufficient capital to fund the Company's operations, which may not be available on terms that are commercially favorable to the Company or at all; provide preclinical and clinical support that the Company's drug formulations are effective against the conditions tested in its preclinical and clinical studies; comply with the term of license agreements with third parties, not to lose the right to use key intellectual property in its business; protect its intellectual property and the timing and success of this intellectual property and achieve acceptance and approval of regulatory filings. Many of these factors that will determine actual results are beyond the Company's ability to control or predict.

這些陳述涉及重大風險、不確定性和假設;包括,公司是否能夠:提供充足的資金並獲得必要的監管部門批准,以便及時成功完成臨床前和臨床研究,以實施其開發計劃;成功實現其藥物配方的商業化;獲得足夠的資金爲公司的運營提供資金,這些資金可能無法以對公司有利的條件獲得,或者根本無法以商業上有利的條件獲得;爲公司的藥物提供臨床前和臨床支持配方對臨床前和臨床研究中測試的條件有效;遵守與第三方簽訂的許可協議條款,不會失去在其業務中使用關鍵知識產權的權利;保護其知識產權以及該知識產權的時機和成功,並獲得監管申報的接受和批准。這些決定實際業績的因素中有許多超出了公司的控制或預測能力。

Readers should not unduly rely on these FLS, which are not a guarantee of future performance. There can be no assurance that FLS will successfully come to fruition, and as such, FLS involve known and unknown risks, uncertainties and other factors which may cause actual results or future events to differ materially from the FLS.

讀者不應過分依賴這些 FLS,它們並不能保證未來的表現。無法保證FLS會成功實現,因此,FLS涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致實際結果或未來事件與FLS存在重大差異。

Although the FLS contained in the press release are based upon what management currently believes to be reasonable assumptions, the Company cannot assure prospective investors that actual results, performance or achievements will be consistent with these FLS.

儘管新聞稿中包含的FLS基於管理層目前認爲的合理假設,但公司無法向潛在投資者保證實際業績、業績或成就將與這些FLS一致。

All FLS are made as of the date hereof and are subject to change. Except as required by law, the Company assumes no obligation to update such statements.

所有FLS均自本文發佈之日起製作,可能會發生變化。除非法律要求,否則公司不承擔更新此類聲明的義務。

For More Information:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)

欲了解更多信息:
1.866.THE.LASE (843.5273)
416.699.LASE (5273)

Kristina Hachey, CPA
Chief Financial Officer
khachey@theralase.com
416.699.LASE (5273) x 224

克里斯蒂娜·哈奇,註冊會計師
首席財務官
khachey@theralase.com
416.699.LASE (5273) x 224

SOURCE: Theralase Technologies Inc.

來源: Theralase 技術有限公司


View source version on accesswire.com:
在 accesswire.com 上查看源代碼版本:

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論